Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Entrada Therapeutics (TRDA) Cash & Equivalents (2022 - 2025)

Entrada Therapeutics has reported Cash & Equivalents over the past 4 years, most recently at $90.4 million for Q4 2025.

  • Quarterly results put Cash & Equivalents at $90.4 million for Q4 2025, down 10.69% from a year ago — trailing twelve months through Dec 2025 was $90.4 million (down 10.69% YoY), and the annual figure for FY2025 was $90.4 million, down 10.69%.
  • Cash & Equivalents for Q4 2025 was $90.4 million at Entrada Therapeutics, down from $93.3 million in the prior quarter.
  • Over the last five years, Cash & Equivalents for TRDA hit a ceiling of $227.6 million in Q1 2023 and a floor of $45.2 million in Q4 2022.
  • Median Cash & Equivalents over the past 4 years was $78.9 million (2023), compared with a mean of $91.1 million.
  • Biggest five-year swings in Cash & Equivalents: surged 168.96% in 2023 and later crashed 69.94% in 2024.
  • Entrada Therapeutics' Cash & Equivalents stood at $45.2 million in 2022, then soared by 49.7% to $67.6 million in 2023, then soared by 49.72% to $101.2 million in 2024, then decreased by 10.69% to $90.4 million in 2025.
  • The last three reported values for Cash & Equivalents were $90.4 million (Q4 2025), $93.3 million (Q3 2025), and $72.5 million (Q2 2025) per Business Quant data.